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ABSTRACT
Chronic venous insufficiency (CVI) is a medical disease caused as a result of
incompetent vein valves in the lower extremities by the failure to reduce venous pressure during
calf exercise. This condition affects 2.5 million individuals in the United States; some estimates
are over 6 million due to undiagnosed cases. Healthy venous flow is characterized by the calf
muscle producing a lower venous pressure with competent vein valves maintaining this reduced
pressure by preventing blood from flowing back into the lower legs; instead of returning to the
heart. Conversely, an individual suffering from CVI has partially or fully incompetent vein
valves which allow retrograde blood flow. The symptoms from the disease can range from a
minor case in which blood pools in the feet, causing swelling and discomfort, to more severe
cases including venous ulcers; potentially leading to disability for patients. Treatment options for
patients with less severe cases include compression sleeves for the affected areas, exercise,
medication, and some minimally invasive, outpatient procedures. Unfortunately, the only
medical alternatives if these treatments prove to be ineffective include more aggressive
interventions to attempt to repair, replace, or transplant new valves to the affected area; however,
these procedures can be technically difficult to perform and are not always effective.
Another option for treatment of CVI that has seen improvement over recent years is the
manufacturing of prosthetic vein valves for implantation into individuals; one of which is using
3-D printing technology to produce bio-compatible valves composed of a PEGDA pre-polymer
solution. In order to test the concept of this approach and to improve the effective design of these
valves, an experimental flow loop derived from a lumped parameter model of the leg venous
system was used. The resting pressure of the system was set to one-half that of the adult
pressures due to the presently available gel material used for the printing of the valves is
ii

inadequate. The system was tuned to match the physiological ankle pressure response during
exercise by the adjustment of specific system parameters to match the ambulatory venous
pressure and recovery time criteria. An ideal venous valve was first tested as a controlled
baseline, and the 3-D printed valves were then tested for utility.
Valves were then tested for the appropriate ambulatory venous pressure response to
verify if the tested valves met the desired physiological criteria. Additionally, a sample of valves
was statistically analyzed to offer information on the capability of the valves, to assess the
consistency in valve printing, and to determine the life cycle of the valves during continuous use.
A Weibull distribution analysis was performed to draw conclusions on the life cycle test results.
In conclusion, the tests showed that the 3-D printed valves are able to satisfy the desired
pressure-related parameters of time to ambulatory venous pressure, mean ambulatory venous
pressure, and recovery time at the reduced system pressure that was one-half of that measured in
an adult patient. The gels require material improvements to handle the normal hydrostatic leg
pressures and longevity. Of the two valve geometries tested, the ‘sinus’ geometry produce more
desirable results in all of the parameters mentioned above, and in the fatigue test.
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CHAPTER ONE
INTRODUCTION TO CHRONIC VENOUS INSUFFICIENCY

Chronic Venous Insufficiency (CVI)
Chronic venous insufficiency (CVI) is a venous disease caused by the failure to reduce
venous pressure during exercise as a result of incompetent vein valves, a condition which is
estimated to effect in the range of 2.5 million to over 6 million Americans [4, 9, 1]. Of the total
number of Americans with CVI, it is estimated that 20 percent will develop venous ulcers [9].
The estimated medical financial burden of CVI is $1 billion annually in the United States alone,
and estimates of $3 billion for Western countries in total [10, 11]. In the United States, loss of
work productivity is estimated to be in excess of $260 billion per year when combining both
complete loss of work productivity or diminished productivity due to physical limitations of
workers [15].
Risk factors for CVI have been found to include, but are not limited to: sex, age, family
medical history of the condition, obesity, and other less common factors [12, 13]. Other factors
which have been associated with CVI are prolonged standing or sitting [13, 14]. When analyzing
the medical costs and related risk factors of CVI, the need for improved treatment options is
necessary.

Enhancing the effectiveness of treatments, improving awareness, or potentially

developing a permanent cure for CVI will have a positive impact on the lives of millions.
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Motivation and Background
With chronic venous insufficiency (CVI), vein valves in the legs do not function
effectively; as a result, during exercise the venous pressure in the legs fails to reduce to proper
levels and blood pooling in the legs occurs. CVI currently affects over 6 million people in the
U.S. [1]. Healthy circulation during exercise is characterized by reduced venous blood pressure
by the contraction and relaxation of the leg muscles, and with the venous valves functioning
competently. The contraction and relaxation of the calf muscle produces a pressure gradient
which lowers the venous pressure, and vein valves assist in maintaining this drop in pressure by
competent function in the opening and closing of the valve leaflets. The ability of deep leg veins
to pump blood upwards is assisted by the contraction of the calf muscles acting as a pump. In
order to prevent blood flow from flowing in the wrong direction, back towards the feet, bicuspid
one-way valves in the veins are forced closed due to the high pressures when the calf muscle
contracts. Ideally, the vein valves should not allow retrograde blood flow; however, incompetent
valves commonly lead to CVI, and reverse blood flow into the lower legs. Incompetent one-way
valves are characterized as valves where the leaflets improperly seal, are under-developed, or
have been absorbed into the vein wall [2]. The result of this condition can cause ulcer formation,
pain, swelling of the feet, and can potentially lead to disability. The goal of this research is to test
and evaluate the viability of 3-D printed biocompatible prosthetic bicuspid valves for
implantation and treatment of CVI.
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Healthy Venous Circulation
To understand the undesirable physiological effects of CVI, it is helpful to first have a
more detailed understanding of a healthy venous anatomy and how the venous system functions
to return blood to the heart. The four components to normal venous circulation are the heart, a
dynamic pressure difference, venous muscle pump, and venous valves [3]. To return blood to the
heart the venous circulation must pump against gravity and a hydrostatic pressure, this is
accomplished by the combined work of the venous pump, competent vein valves, and a dynamic
pressure gradient [4].
Competent vein valves are a series of bicuspid valves, located within the deep and
superficial veins, which function to only allow blood flow to flow upstream, or anterograde flow,
and ensure backflow, also referred to as retrograde flow, to the foot does not occur [5]. Figure
1.1 illustrates the operating principles of how the vein leaflets open and close based upon the
pressure gradient within the vein [6].
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Figure 1.1 Vein Valve Process: From Bazigou and Makinen [6]

The venous system is comprised of three types of veins: superficial, communicating, and
deep veins [7]. Figure 1.2 shows these vein classifications, along with their location with respect
to one another in the body.
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Figure 1.2 Vein classification showing superficial (a), communicating (b), and deep veins: From Meissner et al. [4]

The superficial veins are closest to the surface with the deep veins located deep within
the muscle tissues (shown in Figure 1.2). The communicating veins fill the void between the
superficial and deep veins by connecting the two [7]. As previously mentioned, the main driving
force for blood flow from the legs to the heart is the result of the pumping action of the leg
muscles [7]. As the calf muscle contracts, the deep veins are compressed, resulting in a pressure
increase, and the propelling of blood in the normal direction back toward the heart [7]. The
purposes of competent vein valves are to prevent this blood from regurgitating back to the legs.
This process is illustrated in Figure 1.3.
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Figure 1.3 Venous muscle pump illustration: From Stranden [8]

During ambulation, the venous pressure in the lower leg decreases as the muscle pumps
are pumping blood toward the heart while the vein valves keep reflux from occurring,
incrementally emptying the venous system of blood until an equilibrium between arterial inflow
and venous outflow occurs [5, 4]. Ceasing leg exercises allows the veins to fill, resulting in the
opening of the vein valves and the increase of pressure back to the resting venous pressure [5].

Diagnosis of Chronic Venous Insufficiency
As chronic venous disease is a widespread health condition ranging from minor severity
such as asymptomatic varicose veins to more advanced cases, diagnosis is an important first step
in medical treatment [16]. Due to the statistically high number of Americans effected by a
variety of CVI, many individuals may unknowingly have the disease or are not concerned
enough to consult with a medical professional; as a result, underdiagnoses is a commonality
6

among many patients [17]. As treatment options, surgeries, or special clothing can either remedy
the condition or provide relief to the patient, a standardized classification method to determine
CVI severity is an essential tool in identifying the disease. The CEAP classification (Clinical,
Etiology, Anatomy, Pathophysiology) is a tool in which patient can be medically graded on
severity of CVI. Moreover, it has been proven to be reliable both in utilization and development
of patient specific treatment options [17]. Figures 1.4 and 1.5 below illustrate this process of
classifying lower extremity venous disorders.

Figure 1.4 CEAP classification for CVI: from Hyder et al. [17]
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Figure 1.5 Examples of CEAP Classifications: from Fronken et al. [31]

The CEAP classification is applied in a sequence of steps and results in a severity grade
ranging from C0 to C6; in which C0 is no evidence of the disease and C6 as the most severe case
of open venous ulcers [17]. The first step in the process is “C” or the clinical diagnosis of the
diseases. This step involves a patient or a doctor identifying the existence of CVI, and it is
medically determined that the patient suffers from CVI. After diagnosis, the next step is to
determine the cause of and/or the factors which attributed to the development of the disease
during step “E” or etiology. The third step in the classification process is then to determine the
anatomical cause of the disease, and to attempt to determine the location of the disease. The final
8

step of the process is “P” or pathophysiology. During this step, it is determined whether the
disease was caused by a change in function (i.e. a once competent valve no longer works
effectively), or whether there is a structural defect within the venous system. Nevertheless, the
CEAP classification is primarily simplified now to only the first step, the clinical diagnosis, and
the remaining three steps are often ignored because they are not essential for diagnosis.

Treatment Techniques for Chronic Venous Insufficiency
Compression
Compression therapy (CT) is not only the first treatment option for CVI patients but is
also applicable to all levels of patient severity [5, 18]. Compression wraps and stockings can be
prescribed to a patient at a range of graded external compressions (generally 20-50mmHg); as a
result, it is important for a patient to receive the correct compression level as excessive pressure
may cause the disease to intensify [17]. Compression therapy products include a wide variety of
options anywhere from compression bandages to compression pumps to graduated elastic
compression stockings [18]. To further improve the lives of CVI patients, recent studies have
compared the ease of application for a variety of compression product. A study reported that
86.2% of patients considered progressive elastic compression stockings easy to apply, whereas
graduated elastic compression stockings where easier to apply by 57.1% of patients [19].
Although compression therapy is the easiest treatment option, it has been reported to completely
heal severe venous ulcers after five months [17].
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Exercise
Calf muscle exercises work in conjunction with compression therapy treatment plans
[17]. Calf muscle exercises and leg elevation, in conjunction with other treatment options, have
been observed to heal venous ulcers, reduce symptoms, and decrease the probability of
developing ulcers [20, 7].
Medication
In the United States no pharmacological medicines for treatment of CVI have been
approved; however, small studies have shown that there are plant extracts which can be effective.
One example is a medicine called Daflon, which has resulted in mild improvements of some CVI
symptoms [17, 21, 22]. Medical trials testing the efficacy of hydroxyethylrutoside, a synthetic
derivative of glycoside, have suggested that it may help reduce pain, cramps, and heaviness of
the lower legs. However, results are difficult to infer from such medical trials due to the lack of
quality in the reporting [23]. Moreover, the current medicinal products are only applicable for
temporary relief and require the addition of more permanent treatment methods, such as
compression therapy [17].
Venous Ablation
Venous ablation is the removal of venous tissues, and is a minimally invasive, outpatient
procedure option for CVI patients [24]. Modalities for ablation include thermal, chemical, and
mechano-chemical ablation techniques [24]. A study conducted over 300 patients who
underwent radiofrequency ablation has reported results in which ulcers were healed in almost
90% of patients [25]. A complication of an ablation procedure, specifically radiofrequency
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ablation, is the potential for the development of thrombus; in which treatment is varies from
minor as ultrasound surveillance to anticoagulant therapy for more severe cases [26].
Sclerotherapy
Sclerotherapy is a treatment option in which a fluid that causes the vein to collapse is
injected into the vein. It is a treatment option for varicose veins and spiders veins. The sclerosing
agent is a salt solution and currently only three agents are approved for use in the United States
[17]. The most common downside of sclerotherapy treatment is skin hyperpigmentation around
the treatment site [17].
Venous Ligation and Phlebectomy
The objective of either vein ligation of phlebectomy is to alter the direction of venous
flow. Vein ligation is considered to be the primary surgical treatment of superficial venous
incompetence, and the surgery involves the closing of the vein [24]. Most patients recover within
two weeks and in rare cases deep vein thrombosis may be a complication of the surgery [24].
Phlebectomy is the complete removal of the section of vein [5].
Valve Reconstruction
Valve reconstruction is a treatment option for CVI patient whose disease could not be
adequately treated by compression treatment or superficial venous surgery [27]. Patients who
underwent valve reconstruction for ulceration treatment had a 70% success rate after three years;
however, this value decreased to 50% after five years [28]. Valve auto transplantation, a subset
of valve reconstruction, is the surgical procedure of harvesting a competent valve, testing the
valve with saline, and finally the functioning valve is then implanting the new valve in place of
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the incompetent valve [27]. Auto-transplantation of valves is imperfect with extremely difficult
technical challenges including diameter variations that must be overcome in order to have a
successful operation [28]. Although valve reconstruction is a relatively new treatment for CVI, it
has does have a promising record for treatment of the disease [29]. However, for cases in which
valve reconstruction or transplantation are not an option or have had unsuccessful results, an
artificial valve to replace failed native valves has been increasing over recent decades.

Hypothesis and Objectives
Hypothesis
One purpose of this study is to test the hypothesis that 3-D printed valves composed of a
bio-compatible hydrogel material and two different designs satisfy three main pressure and time
related conditions for treatment for chronic venous insufficiency (CVI). The intent is a proof of
the concept to determine the functional capability, and, if so, identify areas for design
improvement.
Objectives
1. Use a physical system to test 3D printed valves for the follow three criteria:
a. Produce a pressure drop from resting to the ambulatory venous pressure (AVP).
AVP is defined as the minimum venous pressure achieved during ambulation in
which the AVP pressure is at maximum 50% that of the resting pressure.
𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 − 𝐴𝐴𝐴
∗ 100 > 50%
𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
12

b. Valves must be able to drop the venous pressure from resting to AVP in
approximately 10 seconds which is the equivalent of 10 steps during calf exercise.
c. The time it takes for the pressure to return from AVP to resting pressure must be
greater than 20 seconds.
2. Test enough functioning valves to statistically determine consistency in valve
performance.
3. Perform continuous testing of valves to verify that the valves are able to competently
function for an extended period of time, and still satisfy the criteria at outlined in
Objective 1. Additionally, perform a fatigue test to analyze the number of cycles the
valves can function before failure.
4. Compare functional difference between 3-D printed valves with and without a sinus.

Review of Previous Work
To better understand the negative effects of chronic venous insufficiency, it is helpful to
compare the measured differences between a diseased and healthy patient. Figure 1.6 is a model
pressure curve for a healthy venous flow. The venous pressure can be used to determine the
severity of the disease for a patient. According to the work done by Eberhardt and Raffetto the
resting venous pressure for a healthy patient should be in the range of 80-90 mmHg [5]. Upon
the start of the calf exercise, the pressure drop should be greater than 50%, but no lower than 2030 mmHg. This lowered venous pressure is referred to as the Ambulatory Venous Pressure or
AVP. AVP in a healthy patient should be achieved is under 10 seconds from the commencement
of the calf exercise. Once the calf muscle exercise has stopped, the venous pressure should return
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to the resting pressure in no sooner than 20 seconds; this is referred to as the recovery time or RT
[5].

Figure 1.6 Healthy venous pressure curve: From Eberhardt and Raffetto [5]

The pressure curve for the healthy patient can be directly compared to that from a
diseased patient; as shown by Figure 1.7. Regardless of a healthy or diseased patient, the normal
resting pressure of 80-90 mmHg remains similar between the two, as does the time to achieve
AVP is under 10 seconds. However, it can be observed that the pressure drop from resting to
AVP is less than 50%, and the recovery time is faster; reaching the resting pressure in less than
20 seconds [5].
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Figure 1.7 Diseased patient venous pressure curve: From Eberhardt and Raffetto [5]

Moriyana et al. tested valves created from an electrospinning process in a mock
circulatory system. Figure 8 shows the results of their pressure response data. It can be observed
in Figure 1.8 that with the biometric prosthetic venous valve gradually drops the pressure for the
resting state down to ambulatory venous pressure before recovering back to the resting pressure.
The valve meets in criteria outlined by Eberhardt and Raffetto. However, for the open prosthetic
vein valve and the no device cases, the results are insignificant due to the instantaneous pressure
drop and recovery, as compared to Figure 1.7 [5].
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Figure 1.8 Pressure response for a biometric prosthetic venous valve (bPVV), open prosthetic venous valve (oPVV), and a
no valve case: From Moriyama et al. [37]

Research conducted by Meissner et al. obtained results comparable to the venous pressure trace
as that of Eberhardt and Raffetto. Meissner et al. demonstrated a drop to AVP upon walking 7 to 12 steps,
or the equivalent of 10 “the tip-toe maneuvers”, in which the venous pressure was reduced from 100
mmHg to a mean of 22 mmHg, and the time from the stop of exercise until the pressure returned to the
resting pressure was 31 seconds [4]. Their work confirmed and met all of the criteria established by
Eberhardt and Raffetto. The most useful measurements for diagnosis and establishing the severity of CVI
is the mean ambulatory venous pressure and recovery time [5].
Pollack and Wood obtained a resting venous pressure of 86.8 mmHg, a pressure drop of 52
mmHg, and a recovery time of 22.9 seconds, which agrees to the work of Meissner et al. and Eberhardt
16

and Raffetto [38]. The results of the work by Pollack and Wood are illustrated by Figure 1.9. The data
from Pollack and Wood was averaged from a sample of 10 patients each walking at approximately 1.7
mph [38].

Figure 1.9 Clinically measured ankle venous pressure during walking: From Pollack and Wood [38].

Figure 1.10 illustrates the generalized spectrum of the venous pressure, whether a healthy patient
or a patient with a severe case of CVI. A healthy patient obtains a satisfactory AVP and RT in the
appropriate length of time. The classifications of for the severity of CVI and how the venous pressure is
affected are also illustrated.
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Figure 1.10 Venous pressure response at rest and during ambulation and recovery time (RT): From Stranden 2011 [8].

An in vitro mock circulatory system developed by Gorman for testing of a biological valve
produced physiological pressure and flow responses. Gorman first validated the system by testing a check
valve. The result of the check valve was a pressure drop from 89.4 mmHg down to 6.7 mmHg with a
lengthy recovery time of 40.0 seconds [33]. These results agree with the work of Eberhardt and Raffeto,
and Pollack and Wood. Gorman also showed a 40% drop from resting pressure after 10 cycles and an
80% pressure drop after 20 cycles [33]. The conclusion from this data is the majority of the pressure drop
occurs early on during exercises, as discussed in the work of Meissner et al [4].
Chopp modified the system developed by Gorman to test the first generation of 3-D valves from
Rice University. These valves operated at a maximum resting pressure of 20 mmHg; approximately onequarter the full scale pressures measured in an adult human [34].
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CHAPTER TWO
METHODS

Introduction to Lumped Parameter Modeling
The concepts of equivalent electric circuits can be directly carried over to model fluid
circuits. A lumped parameter model (LPM) allows continuous system to be discretized into
individual zero-dimensional components (“lumps”) representing the regional characteristics of
the system. A LPM results in a circuit containing resistance, capacitance, and inductance
elements which preserve the overall dynamic behavior of the system. The LPM established by
Snyder and Rideout (Figure 2.1) was the first one widely accepted for the entire human blood
circulation; however, the focal point of this research is within the “Legs” component of the
model.
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Figure 2.1 Lumped parameter model of human circulation: From Snyder and Rideout [32]

The model used in this research represents a single human leg. It further simplifies the
“Legs” portion of the Snyder and Rideout by reducing components and applying information
from literature to provide boundary conditions, while preserving the equivalent characteristics of
the overall system [33]. The final LPM used as the basis for the flow loop is shown in Figure 2.2.
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Figure 2.2 Lumped parameter model for testing of 3D printed valves

Table 2.1 Abbreviation key for Figure 12.

Abbreviation
mp
sve
fem
ivc
vb
source
hydro

Full Name
Muscle Pump
Small Veins
Femoral
Inferior Vena Cava
Vascular Bed
Source Pressure
(Arterial)
Hydrostatic
pressure generator

Tracing the LPM from the abdomen to capillary flow the Pivc pressure is around 3 – 5 mmHg with
a hydrostatic pressure generator of 75 mmHg. The approximated pressure losses due to the Rfem and Rsve
cause a total pressure loss of 5 mmHg. As a result, the Psource (ankle pressure) is 85 mmHg. However,
variations in pressures and resistances achieve a range of ankle pressures that have been measured
clinically to be 80 – 90 mmHg.
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Overview of Flow Loop Components
The flow loop used for these experiments contains various components in order to realize
the LPM into a table-top experimental setup. The ‘Test Section’ in Figure 9 is the location, in
which the 3-D printed valves, or check valve, are inserted into the flow loop. Resistance
elements in the model are categorized as either resistors due to valves or tubes. Resistance (R) in
a fluid circuit is expressed by Equation 2.1.

𝑅=

∆𝑃

(2.1)

𝑄

Where ΔP presents the pressure drop across the resistor or any two points in the system
and Q is the flowrate through the resistor [35]. This equation assumes that the flow is laminar; if
the flow were fully turbulent the pressure drop factor in Equation 1 would become ΔP0.5 [35].
Resistance in the flow loop can be determined by using pressure transducers and a flow probe to
measure the flow rate. Resistance in the flow loop is controlled by a combination of needle and
ball valves and the resistance presented by the tubing itself.
Compliance elements in the system are used to represent the transmural pressure vs.
volume behavior of various compartments of the circulation. Compliance elements are necessary
in order to simulate the “elasticity” of the blood vessels when using rigid tubing in the flow loop.
Compliance (C) in a fluid circuit is given by Equation 2.2.

𝐶=

∆𝑉

(2.2)

∆𝑃

Where ΔV is the change in volume and ΔP is the change in pressure [35]. Compliance
elements in the flow loop consist of air chambers and an elastic section tube. In the case of the
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muscle pump the transmural pressure is specified in an elastic tube, because it is the varying
external pressure applied by the calf muscle upon the deep veins (represented by the elastic
section of tubing in the muscle pump) that powers the pumping action. For static compliance
elements, it is more practical to use air chambers as compliance elements. These air chambers
emulate the ‘elasticity’ by the volume of trapped air to be decrease as the water level increase;
mimicking the expansion of a blood vessel. The compliance of the air chambers used in the flow
loop can be calculated using Equation 2.3.

𝐶=

𝑉

(2.3)

𝑛𝑛

Where V is the volume of trapped air, P is the absolute pressure, and n is the process
factor. The value for the process factor is taken as 1, but can be as high as 1.4 [35].
Resistance Elements
Resistance in a flow loop is an inherent parameter that exists due to the physics of fluid
flow. Resistance elements exhibit a non-linear behavior. It is necessary to be aware of this
because non-linear flow (i.e. turbulence) will cause inaccurate readings for flow and pressure as
those elements are linear. Non-linear effects such as turbulence are undesirable for this research.
When it comes to modeling the human circulation, being able to adjust the resistance is a vital
aspect for proper simulation of flow. There are two main types of resistance on the system:
valves and tube resistance. Valves are used primarily to apply significant resistance to fluid
because using tubing to apply the equivalent level of resistance would require excessive lengths
of tubing. The two types of valves used in the flow loop are ball valves and needle valves. The
benefit to using a ball valve, as shown in Figure 2.3 below, is its ease of adjustment and the
ability to change the resistance from minimal (when the valve is completely open) to its
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maximum resistance (right before the valve is fully closed). However, one drawback of a ball
valve used is its inaccurate resistance value as there are no discernable markings for how open or
closed the valve is; other than when fully open or closed. Inconvenient, but this can be adjusted
by the operator. Further, ball valves suffer from resistance nonlinearities at higher flow rates but
this was not considered to be a pertinent factor for the flow rates in this study.

Figure 2.3 Ball valve resistance element

The other valve used in the system is referred to as a needle valve, see Figure 2.4. The
function of this valve is the same as that of the ball valve, which is to provide resistance to fluid
flow. A needle valve uses needle shaped plunger which can be adjusted to control the area in
which fluid can flow; as a result, altering the level of resistance. Nevertheless, the major
advantage of a needle valve is its precise adjustments which are marked by a number-color
combination. This allows for the resistance to be adjusted and easily returned to a specific
resistance setting and benefits from repeatability. Needle valves also suffer from nonlinearities in
resistance to flow rate, but this was not considered a pertinent factor in this study.
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Figure 2.4 Needle valve resistance element

The other form of resistance in the flow loop is the inherent resistance to fluid flow when
the flow passes through a conduit as a result of friction on the surface of the walls. In the case of
this system, the fluid conduit of varying sizes also subjects a resistance to flow. The value for
this type of resistance can be calculated by using Equation 2.4; which is for laminar flow through
a horizontal pipe.

𝑅=

128𝜇𝜇

(2.4)

𝜋𝜋𝐷4

where L is the length of tube, D is the inner diameter of the tube, 𝜌 is the density of the fluid, and

𝜇 is the dynamic viscosity of the fluid [36]. Hence, a flow element shows a linear resistance
under laminar flow conditions. Although the majority of the resistance to flow is a result of the

valves installed into the system, it is important to minimize tubing length when possible and
design the system with awareness of the resistance caused by tubing. The tubing used in the
system is commercial grade silicone tubing designed for water applications.
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Compliance Elements
Compliance elements are used to simulate the natural expansion and contraction of the
blood vessels and organs. In the mock circulatory system, two different compliance elements are
utilized. The first is an air chamber compliance element, shown in Figure 2.5. These operate by
the compression and expansion of the trapped air volume as the water levels rises and falls due to
the operation of the muscle pump. Refer to Equations 2.2 and 2.3 for how compliance values can
be quantified. The compliance values for these air chambers are adjusted by varying the volume
of trapped air.

Figure 2.5 Air chamber compliance element

The second type of compliance element used is a section of highly elastic section of
tubing (Figure 2.6). This compliance elements simulates the elasticity of blood vesssels by the
stretching of the tubing, which allow for the internal fluid volume to change as a result of a
change in pressure. The compliance value for this element is controlled by adding clamps to
decrease the overall surface area of the tubing that can expand.
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Clamp

Figure 2.6 Flexible Compliance Element

Muscle Pump
In order to mimic the calf muscle in the mock circulatory system, a pressure vessel
containing an elastic silicone tubing is used (Figure 2.7) in the flow loop system. The inside of
the chamber is sealed to allow accurate time-dependent control of the pressure inside the air
chamber. The inner silicone tube is compressed and relaxed as the liquid blood simulant flows
through it (simulating the calf muscle in the human leg compressing on blood vessels during
ambulation). This is a result of the supplyied high pressure air being ported into and evacuated
out of the air chamber.

Pmp

Figure 2.7 Muscle Pump
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The muscle pump primarily acts as to incrementally force the blood simulant through the
venous system, but also acts as a compliance element. As the amount of pressure inside the air
chamber can be controlled and the volume of air is known, its compliance value can be
calculated using Equation 2.
In order to control the muscle pump, the scheme shown in Figure 2.8 is used to replicate
the calf muscle. As previously mentioned, the muscle pump is physically simulated by using a
flexible silicon tub enclosed within a sealed air chamber.

Figure 2.8 Control scheme for mock muscle pump [2]

The muscle pump signal alternates the high and low pressure air inputs in the air chamber
by controlling the opening and closing of a MAC valve (MAC Model ISO 3, MAC Valves,
Wixom, MI). The MAC valve is electronically actuated by a voltage signal from a DAQ (data
acquisition) system (NI USB-6211 and NI LabVIEW 14.0.1, National Instruments, Austin, TX).
The MAC valve selected for the system was chosen as it contained two inlets (for the high and
low pressure sources), and multiple outlets for the muscle pump air chamber and venting to
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atmosphere. Another added benefit of MAC valves are their very low air resistance and a robust,
consistent operation. The MAC valve position is precisely controlled by the voltage signal from
the LabVIEW program as a result of two modifiable parameters: duty ratio and step period of the
muscle pump. The LabVIEW program, in combination with the pressure regulator, controls the
shape of the venous pressure signal. Using these controls, the calf muscle element in the system
can be set to imitate the operation of the calf muscle and to produce a physiologically accurate
pressure signal.

Test Section
The test section in the mock circulatory system is located between the calf muscle pump
and the femoral vein resistance, representing, the function of deep venous valves in the vicinity
of the knee. The mock circulatory system is run with a variety of test sections to first determine
that the system functions as required and then to experimentally test different 3-D printed valve
geometries.
No valve
A ‘no valve’ test case was also tested; shown by Figure 2.9. The significance of this ‘Test
Section’ was to understand the effects on the leg venous pressure in the complete absence of a
valve, or in which the valve is entirely incompetent at preventing backflow.
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Figure 2.9 No valve test section

Mechanical Check Valve
A mechanical check valve (Figure 2.10) with an acceptable minimum opening pressure
was selected to serve as an ideal venous valve. An ideal vein valve is defined as a valve which
has no reflux flow upon full closure of the valve; in other words, once the check is closed no
regurgitant flow is permitted to flow back into the lower leg, maximizing the recovery time.
Additionally, it is ideal that there is zero forward flow pressure drop slowing the flow of blood
returning to the heart.

Figure 2.10 Mechanical check valve

The mechanical check valve was also used in tuning of the mock circulatory system
before the 3-D printed valves were tested. The system’s resistance and compliance values were

30

adjusted until the pressure trace for the venous pressure showed the desired pressure signal as
outline in literature (AVP and RT). This tuning procedure was performed in order to minimize
additional tuning once the 3-D printed valves were exchanged for the mechanical check valve as
the ‘Test Section’.
3-D Printed Biocompatible Valve
Let it be acknowledged the support from collaborators Samantha J. Paulsen and Jordan S.
Miller, Rice University, Houston, TX for the design, fabrication, and technical details regarding
the 3-D printed valves made from hydrogel was invaluable for this study. An example of one of
the geometries tested is shown in Figure 2.11. These valves are designed to allow no reflux flow
during full closure of the leaflets.

Sinus
Flow

Leaflet

Figure 2.11 3-D Printed valve schematic: From Samantha J. Paulsen and Jordan S. Miller, Rice University, Houston, TX
[40]

A second valve geometry that was also tested was a valve without sinus. These two valve
geometries were tested in the system to see if there was a functional difference or benefit of one
design over the other.
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The bicuspid 3-D valves were initially based on the geometry of a 3-D printed human
aortic valve available from the NIH 3D Print exchange (Model ID 3DPX-000452). CAD
software was used to modify the structures and generate the final 3-D model to be pre-processed
into slices using CreationWorkshop software. The assemblies, called “gels”, were fabricated
using a 80% w/w (mass fraction) with a one-to-one ratio 6:35 kDa PEGDA pre-polymer
solution; where kiloDaltons (kDa) is a unit of molecular mass. The gels were printed in layers of
50 µm and exposed to light to obtain the desired mechanical and physical properties using a
stereolithography fabrication technique [40].
Initial valve geometries were determined to lack sufficient strength to withstand testing
and the printing procedure was modified to improve the strength and stiffness of the gels.
Additionally, the valve geometry was modified to increase the leaflet length to increase the
contact length of the two leaflets when closed. The first and second generation material
properties of the gels are shown in Table 2.2. Under normal adult conditions, valves would be
expected to withstand hydrostatic pressures on the order of up to 100 mmHg. The hydrogel
valves tested here were unable to withstand such pressures. Accordingly, tests were scaled to
operate at a maximum of 50 mmHg to further the proof of the concept and to examine
functionality and design practices for a future generation of hydrogel valves.
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Table 2.2 Material Properties of 3-D Valves: From Samantha J. Paulsen and Jordan S. Miller, Rice University, Houston,
TX [40]

Gel Material Properties
Material Property
Young's Modulus
[kPa]

1st
2nd
Generation Generation
20

65

Poisson's Ratio [-]

0.39

0.49

Density [g/cm3]

1.00

1.05

Measurement Devices
Flow Rate Measurements
Flow through the mock circulatory system was measured by a flow probe and flow meter
(P600 Flow Probe and FM 501 Square-Wave Electromagnetic Blood Flowmeter, Carolina
Medical Electronics, East Bend, NC); shown in Figure 2.12 and 2.13, respectively. The flow
probe was placed within the system downstream of the ‘Test Section’ as a method to determine if
the valve functions to stop flow when fully closed. The flow probe is connected to the flow
meter, and the flow meter is connected to the NI DAQ in order to allow for the flow
measurements to be displayed and recorded during testing. The flow probe uncertainty is +/- 2%
of the flow rate; as stated by Carolina Medical.
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Figure 2.12 Carolina Medical Flow Meter

The flow meter must be grounded to reduce noise; this was done by placing a stainless
steel hose barb inside the system downstream the flow probe to act as a grounding source. As the
flow probe operates by creating an electromagnetic field between the two contacts in the flow
probe, the fluid solution must contain electrolytes. This was achieved by using a saline solution
which has the correct salt concentration as that of human blood (approximately 8-10g of salt per
1L of water). A saline solution with too little salt would result in inaccurate flow measurements.

Figure 2.13 Carolina Medical Flow Probe (30mm circumference)
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The procedure for start up, zeroing, and operating of the flow probe and flow meter
combination was performed in accordance with the provided manual from Carolina Medical
Electronics. The manufacturer supplied probe factor for saline was used.
Pressure Measurements
Pressure measurements were recorded using medical grade pressure transducers (BD
DTX PlusTM, BD Medical Systems, Sandy, UT). Pressure data was recorded at pre-determined
location within the flow loop by installing pressure taps; the most important being the venous
pressure being measured upstream of the calf muscle pump. The pressure transducers (Figure
2.14) were connected to the pressure taps, and the proper calibration procedure for the amplifiers
was performed by using known heights above and below the transducer’s datum line to ensure
the proper pressure is read. The heights are measured in cmH2O and converted to mmHg to
verify the pressure readings. This procedure consists of defining a null reference by adjusting the
amplifier trim until the pressure reads zero. The pressure was then varied using known pressure
values and the amplifier gain is adjusted until the correct pressure value is recorded. As the
calibration relationship for the transducers is linear; therefore, a minimum of two points had to
be verified to accurately calibrate the pressure transducers.
The uncertainty of the uncalibrated pressure transducers is +/- 2% of the reading or +/- 1
mmHg, as specified by the manufacturer. As the nominal pressure of the system was established
at 46 mmHg, the uncertainty in the pressure measurements is +/- 0.9 mmHg.
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Datum line

Figure 2.14 Pressure transducers

The signal amplifiers used with these pressure transducers results in an output signal as a
differential voltage. The DTXPlus is a full-bridge pressure transducer. The amplifier box
supplies bridge excitation, and converts the small differential signal of the transducer to a singleended output voltage in the +/- 10V range relative to the instrument ground. The amplifiers are
then connected to the DAQ and the differential voltage is converted to quantifiable pressure
measurements in mmHg.

Data Collection
NI LabVIEW
As previously mentioned, NI LabVIEW was used for displaying and recording both
pressure and flow data. An in-house LabVIEW program was used to run the mock circulatory
system parameters and to save all of the experimental data in files. The NI USB-6211 16-bit
analog inputs in the +/- 10V range, and is used as the control signal for the MAC valve.
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Setup of System Components
The following section overviews the setup required for each component of the mock
circulatory system prior to testing. The most important aspect is to allow appropriate time for all
system components to reach a steady-state operating point. In order to setup the measurement
devices (pressure and flow rate), it is necessary that the LabVIEW software is running as it is
used to display the pressure and flow rate readings during those steps. System tuning is
necessarily iterative as the several control elements (resistance and compliance) interact with
each other.
Water Pump
The water pump which maintains a constant head for the source pressure and flow
through the system must be turned on. In order to have a control of the rate at which water if
pumped, the pump is connected to a variable autotransformer which allows for adjustment of the
pump flow rate. The importance of using an autotransformer is to limit the pump from operating
at its full capacity if it was plugged directly into a wall outlet. It is good practice to allow the
water pump to run for a 5-10 minute warm up period to reach its steady-state operating point.
The supplied voltage to the water pump is adjusted to provide precisely enough flow to the
source head tank such that the water level remains constant. The pump voltage is adjusted to
reach a steady operation point in which the water level of the constant volume head tank barely
crossovers the overflow drain; indicating a steady state flow condition of the fluid entering the
flow loop.
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Flow Meters
To operate the mock circulatory system, the initial step is to prepare all of the
measurement devices. The flow meter requires a warm-up time (approximately 20-30 minutes)
before use. Once the flow meter is at its operating temperature, the procedure for calibrating the
flow probe is initiated.
Pressure Transducers
The pressure transducers are connected to the appropriate pressure taps and the lines
purged of any air by use of a syringe to pull saline-water solution through the pressure lines. The
pressure readings can be verified based on the height differential between the head tanks and the
datum line on the pressure transducers.
High Pressure Air Source
The high pressure line was turned on and the pressure regulator for the high pressure
source is set to the appropriate value. The phenomenon of hysteresis is important to take note of
when the pressure regulators are set. As pressure regulators operate mechanically with a system
of springs and seals with inherent friction, pressure regulators need to be open until the desired
pressure is reached. If the desired pressure is surpassed, the regulators are closed until the
pressure is then below the desired value, and is lastly opened again until the objective pressure is
achieved.
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System Tuning and Testing of Valves
With all of the measurement devices set up, water pump operating, and the high pressure
air supply set, the final step is to then run the system with the desired test section. As previously
mentioned, before testing the 3-D printed valves the system is run with the mechanical check
valve as the ‘Test Section’ in order to set the compliance and resistance values to achieve the
desired pressure trace. This reduces the time required for tuning during testing of the 3-D printed
valves.
System Constraints
The mock circulatory system has multiple compliance and resistance elements which
need to be adjusted in order to obtain the correct pressure and flow rate values during testing.
There are both resistance and compliance elements both upstream and downstream to the ‘Test
Section’ which need to be accounted for. The mathematical expressions dictating the compliance
and resistance values are found in the Overview of Flow Components section with Equations 2.1,
2.2, and 2.3.
Additionally, if the venous pressure is too high or too low the height of the head tanks
can be adjusted to achieve the desired values are per what has been clinically measured.
Venous Pressure Verification
Once the mock circulatory system is at full operational capacity, the system is run by
initiating the LabVIEW program to operate the MAC valve, and to record and save the
measurements for flow rate and pressure. As discussed in literature, the criterion analyzed after
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the data is collected is the time to reach AVP, mean AVP, and RT. These three criteria are then
statistically analyzed to assess the effectiveness of the valves.

Flow Loop
A detailed diagram labeling all of the flow loop components is shown by Figure 2.15.
The acronyms for the labels are the same as used in the circuit diagram (Figure 2.2) and are
described in Table 2.1. The venous pressure is measured downstream to the muscle pump. Flow
measurements are collected upstream of the ‘Test Section’.

Psource

Pivc+hydro

Test Section
Rvb

Csve

Flow Measurement
Cmp

Cfem

Rsve
Rfem
Pressure Measurement

Figure 2.15 Detailed flow loop with labels for all system components
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Rivc

Test Procedure
The specific test procedure following when testing the 3-D printed valves upon the
correct setup of the system components (as previously discussed) is outlined as follows:
1. Set the desired heights of the two head tanks (labeled Pivc+hydro and Psource). The height of
these head tanks (107.5 cmH2O and 54.5 cmH2O for the Pivc+hydro and Psource,
respectively), along with system resistances, determines the resting pressure. The image
of the flow loop in Figure 2.15 has the height of the head tanks set for one-half clinical
pressures (i.e. 45 mmHg compared to 80-90 mmHg for an adult patient). This will be the
operation pressure for the testing conducting in this research.
2. Insert desired ‘Test Section’ into the mock circulatory system.
3. Using the NI LabVIEW program, the resting pressure is displayed and adjusts can be
made in the system to obtain the desired resting pressure. For the testing of the 3-D
printed valves, the resting pressure was set to be 41.6 – 47.6 mmHg.
4. The NI LabVIEW has the capability to adjust the time step and the duration of the
contraction of the muscle pump. For testing the time step was established to be 1 second.
This value was chosen due to the information of literature in which AVP must be
achieved in under 10 seconds, 7 to 12 steps, or 10 heel raises. Additionally, the NI
LabVIEW programs controls the duration of the rest. For most cases exercises lasted for
40 seconds and data was collected 5 seconds before and 40 seconds after exercise.
5. The system settings included a steady state flow rate of 0.08 – 0.125 L/min and a venous
pressure of 41.6 – 47.6 mmHg. The pressure and flow rate for the ‘no sinus’ geometry
had to be tuned to slightly lower values in order to achieve functionality of the valves.
This difference in the tuning will be discussed later on when comparing the performance
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of the valves. Additionally the system was tuned with the following resistance and
compliance values are summarized in Table 2.3.
Table 2.3 System Parameters for Flow Loop

Component
Name
Rvb
Rsve
Csve
Pmp
Rfem
Cfem
Rivc

Value (or Range)
16.32 – 25.5 mmHg*s/mL
1.6 – 1.9 mmHg*s/mL
0.74 mL/mmHg
344 mmHg
1.3 – 1.55 mmHg*s/mL
2.78 mL/mmHg
0.6 – 1.05 mmHg*s/mL

6. The system is now turned on to begin the testing. If the desired AVP drop or RT is not
achieved, the system resistance and compliance parameters are adjusted. RT is obtained
by using the voltage trace on the NI LabView file to determine the start of recovery; this
is when the MAC valve vacates the air inside the muscle pump chamber. The end time
for recovery is obtained once the mean resting pressure is measured. The time difference
between these values is calculated as the RT. The time to reach AVP is determined by the
number of seconds (or time steps) performed until the pressure curve reaches a ‘constant’
stop for the pressure curve (i.e. the pressure curve stops decreasing).
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CHAPTER THREE
RESULTS AND DISCUSSION
Overview of Valve Geometries Tested
Two valve geometries were tested to compare any operational differences or advantages
of the two designs. These valves were also compared against the mechanical check valve
discussed in the next section. The two geometries were identical with the exception of a ‘no
sinus’ or ‘sinus’ design (shown in Figure 3.1). The material properties for the two designs are
equal as discussed previously; along with no differences in the printing process. Figure 3.2
shows a photograph of the printed 3-D valves before testing.

a

b
Sinus

No Sinus

Flow

Figure 3.1 Valve with 'sinus' (a) and valve with ' no sinus' (b): From Samantha J. Paulsen and Jordan S. Miller, Rice
University, Houston, TX [40]
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a

b

Figure 3.2 Printed gel valve with 'sinus' (a) and valve with ' no sinus' (b)

System Validation
Prior to testing the 3-D printed valves in the flow loop, the system was first validated
using a mechanical check valve as an “ideal” valve. This valve was chosen due to a low opening
pressure and the valve does not allow any backflow when closed. Shown by Figure 3.3 is the
pressure curve for the tested mechanical valve.
Figure 3.3 also graphically represents the pressure response criteria of time to ambulatory
venous pressure, mean ambulatory venous pressure (AVP), and the recovery time (RT). As the
muscle pump time step is set to one second (as mentioned previously), one second is equivalent
to one step for a patient during the calf exercises. The analytical methods used to determine these
three criteria were discussed previously in the Test Procedure section.
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Figure 3.3 Mechanical gate valve pressure results

The pressure results for the mechanical check valve will represent the “ideal” valve, and
will be used as a comparison for the results of the 3-D printed valves. The check valve ‘Test
Section’ achieved a 67.7% reduction in venous pressure (from 46.6 mmHg to 15.0 mmHg) in 8
seconds and a recovery time of 9.9 seconds after 40 cycles (or steps) of the muscle pump were
completed. As a result, the mechanical check valve satisfies all pressure criteria for a competent
vein valve. For the purposes of this study, the valves need to produce a reduction of venous
pressure of 50% or more, reach AVP in ten seconds or less, and have a recovery time of
approximately 10 seconds or longer.
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A recovery time in a healthy adult patient is to be 20 seconds or longer; however, with
the reduced system pressures (approximately 42-47 mmHg) required due to the limitations of the
3-D printed valves a RT of 10 seconds or longer scales proportionally to a RT of 20 seconds or
more for full scale system pressures (80-90 mmHg). This is a result of the system recovering 2030 mmHg from AVP to resting, as opposed to 50-60 mmHg; therefore, the required time to
recover the venous pressure from AVP to the resting takes less time. The results for the
mechanical check valve serve not only as a validation for the system, but also as a point of
comparison for the 3-D printed valves.
After system validation using the mechanical check valves as an “ideal” valve, the 3-D
printed valves were tested. During initial testing of the valves, various defects were observed;
resulting in interesting results. The observed failure modes were: (1) failure of one leaflet, (2)
failure of 2 leaflets, and (3) a single functioning leaflet with the second leaflet being too rigid.
Figure 3.4 shows a ‘no sinus’ valve which competently functioned for two cycles (i.e. the valve
fully opened and closed twice) before one of the leaflets became dislodged from the body of the
valve; resulting in a “partially incompetent” valve. It can be observed for the first operation
cycles of the muscle pump that the venous pressure was decreasing; however, after the third
cycle the pressure increases due to the failure of one of the valve’s leaflets.
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Figure 3.4 Single leaflet failure of 'no sinus' geometry; “partially incompetent” valve

While the valve had two functioning leaflets, it appeared that the valve was properly
functioning due to the decreasing venous pressure. Once the one leaflet failed, there was an
increase in the achieved AVP as the valve was allowing backflow; leading to an increase in the
measured venous pressure. Nevertheless, with a single operational leaflet, the system still
maintained a drop in venous pressure that was 39.3% lower than the resting pressure of 41.9
mmHg. Although the AVP pressure criterion is not satisfied, this result shows the sensitivity of
the system to detect defects and/or variations in the performance of the valves.
The second failure observed was a ‘no sinus’ geometry in which both leaflets functioned
for ten cycles before both leaflets became dislodged; resulting in a “fully incompetent” valve
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(see Figure 3.5). The pressure curve returned to the resting pressure and resulted in the ‘no
valve” scenario as observed by Gorman [33].
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Figure 3.5 Double leaflet failure of 'no sinus' geometry; “fully incompetent” valve

In Figure 3.5, pressure fluctuations are still visible after both leaflets become dislodged
due to the continued operation of the muscle pump. However, with the now “fully incompetent”
valve, the system is unable to maintain any reduce in the venous pressure. This is a result of
blood simulant being able to freely back and forth through the valve. Shown by Figure 3.6 is the
‘no valve’ test case in which the ‘Test Section’ in the system is a length of tubing which
simulates the complete absence of a valve.
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Figure 3.6 'No valve’ pressure curve simulating absence of venous valve

In Figure 3.6, the pressure fluctuations occur due to the muscle pump operating (just as in
Figure 3.5). The inability to reduce the venous pressure is due to the lack of a valve to prevent
backflow of fluid; as also observed in Figure 3.5 for times greater than 20 seconds.
The third recorded valve defect was a ‘sinus’ geometry valve in which one leaflet had a
printing defect; preventing any movement of the leaflet. The one leaflet attempted to close the
valve; however, it was unable to do this effectively due to the increased distance required for the
leaflet to travel in order to make contact with the other leaflet. This case is shown by Figure 3.7.
The other leaflet freely moved, however, no valve closure was observed to prevent backflow.
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Figure 3.7 'Sinus' valve geometry with rigid leaflet

The valve produced an AVP value of 33.1 mmHg, only a 19.7% drop in pressure from the steady
state pressure of 41.3 mmHg. The valve did not fail catastrophically as with the other two cases
discussed; however, the RT was nearly instantaneous at 1.2 seconds and the pressure drop was
insufficient. Nevertheless, these observed failures and/or defects show the ability of the system to
distinguish between competent, defect free valves, and those with minor or major defects.
After the system was validated using a mechanical gate valve as the “ideal” valve to provide a
control case, and the pressure plots of defective 3-D valve to illustrate the ability of the system to detect
“bad” valves, the further testing of the 3-D printed valves was conducted.
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Pressure Plots of 3-D Printed Valves
As a result of the limitations in the material strength (also referred to as pressurehandling) of the 3-D printed valves, the steady state resting pressure was set to a range of 41.6 to
47.6 mmHg during testing; as was the validation using the mechanical check valve. The resting
pressure value varied depending upon the tested valve to obtain the best tuning result for each
specimen testing; due to inherent variability in the valve manufacturing. As compared to the
model outline by Eberhardt and Raffetto, the resting pressure for these experiments was about
one-half of the measured clinical resting pressure value [5]. The scaled down pressures was
determined to be the operating limit of the valves due to their strength. Furthermore, the flow
rate was required to be adjusted during testing until the valves functioned properly; steady state
flow rate varied from 0.08 to 0.125 L/min. Valves were tested during 40 seconds of simulated
calf exercise, with a one second the time step for the muscle pump. Hence, 40 seconds equaling
40 simulated steps or 40 calf raises.
The first generation of 3-D valves, previously tested by Chopp, produced desirable results
at a maximum resting pressure of one-quarter scale clinical pressure (approximately 20 mmHg)
[34]. The valves tested by Chopp also only consisted of the ‘sinus’ geometry [34]. To improve
the maximum pressure handling of the valves, adjustments to the mechanical properties and
geometry of the valves were made at Rice University. The material strength was improved by
adjusting the gel composition and exposure time to UV light during printing to increase the
rigidity of the leaflets. Additionally, the leaflet lengths were increased to improve contact when
the valves are in the closed position. These modifications improved the pressure handling, that is
the maximum pressure the valves can withstand, of the valves to withstand the one-half scale
clinical pressures. A comparison of the “old” and “new” leaflet design for the ‘sinus’ geometry is
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shown by Figure 3.8; the ‘no sinus’ valve geometry has matching leaflet dimensions to that of
the new ‘sinus’ valves.
b

a

Figure 3.8 Updated valve geometry for "old" (a) and "new" (b) leaflet dimensions: From Samantha J. Paulsen and
Jordan S. Miller, Rice University, Houston, TX [40]

The representative pressure plot of the valves with a ‘sinus’ is shown in Figure 3.9(a).
This valve achieved ambulatory venous pressure (AVP) in 8 seconds (or steps) to a pressure of
17.2 mmHg (a 62.9% reduction in venous pressure from 46.4 mmHg) with a recovery time (RT)
of 7.9 seconds after the muscle pump completed the 40 cycles. Similarly, a representative plot
for a ‘no sinus’ is shown by Figure 3.9(b). The valve reached AVP in 8 seconds to a lower
pressure of 13.0 mmHg (a drop of 69.7% from the resting pressure of 42.9 mmHg), but the RT
was shorter at 4.6 seconds. The ‘sinus’ valve had a 29.2 reduction in venous pressure, compared
to 29.9 for the ‘no sinus’ geometry. Therefore, although the ‘no sinus’ valve had a higher
percentage drop in pressure, the actual change in pressure (the difference between resting and
mean AVP) agreed to within 2.3% of one another. The RT criterion for a healthy patient of a RT
greater than 20 seconds [5]. The “ideal” mechanical valve had a measured RT of 9.9 seconds at
these reduced system pressures; as a result, it is expected that most gel valves will produce a RT
of less than 9.9 seconds. Therefore, the recovery time of the gels is anticipated to be shorter due
to the reduced system pressures; meaning less pressure has to be recovered upon ceasing the
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muscle pump action. The drop in venous pressure was approximately 20-30 mmHg for testing of
the 3-D valves as compared to 50-60 mmHg for the pressure drop measured clinically. As a
result, since the pressure does not drop as far as clinical cases, it can be expected that this also
requires a shorter amount of time to recovery back to the resting pressure.

a

b

RT

RT

Figure 3.9 Representative plots for ‘sinus’ (a) and ‘no sinus’ geometries (b)

Although the total operating times of the two valves were different, that does not affect
their ability to be compared. This is due to once either valve reaches AVP, the pressure curves
stabilize at an overall slope of zero (i.e. mean AVP remains constant) before the pressure
increases once the muscle pump stops.
Sample sizes of N=19 and N=10 were collected for the ‘sinus’ and ‘no sinus’ geometries,
respectively. The above plots are representative of the mean results for both geometries. Further
statistical analysis will be discussed below in the ‘Statistical Analysis of Results’ section.
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Statistical Analysis of Results
As previously mentioned, two sample sets, each consisting of samples of one type of
valve geometry, were tested for the effectiveness of valves reproducing the desired pressure
results. This analysis was necessary due to the inherent variations or defects in the valves which
arising during manufacturing. Shown in Table 3.1 are the results for valves with a ‘sinus’.
Table 3.1 Statistical results of valve with 'sinus' geometry

Geometry: Valve with Sinus (N=19)
Mean Standard Deviation
Resting Pressure
46.1
1.5
[mmHg]

Range
42.0 – 47.6

AVP [mmHg]

15.2

4.3

6.5 - 23.5

Pressure Drop [%]

67.1%

8.9%

50.3% - 86.0%

RT [sec]

7.68

3.37

4.0 - 14.6

Time to AVP [sec]

8

1.5

6.0 - 12.0

The mean AVP achieved for the 19 samples tested was 15.2 mmHg with a 67.1% drop in
pressure from resting to AVP. As the goal is a pressure drop of greater than 50%, the valves
satisfied that criterion with a maximum pressure drop of 86.0% and a minimum of 50.3%. As a
result, all of the valves tested were within the range of a healthy patient with regards to AVP.
Recovery time had a mean value of 7.68 seconds, with longest and shortest recovery
times measured as 14.6 seconds and 4.0 seconds, respectively. Considering the entire median of
the data set, 50% of the valves tested had a recovery time of 7.9 seconds or greater. The time to
achieve AVP for all valves was under 10 seconds; as a result, satisfying the time to AVP
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criterion outlined in clinical tests. The results obtained for the ‘no sinus’ geometry are
summarized in Table 3.2.
Table 3.2 Statistical results of valve with ' no sinus' geometry

Geometry: Valve with No Sinus (N=10)
Standard
Mean
Deviation
Resting Pressure
44.6
1.9
[mmHg]

Range
41.6 – 46.7

AVP [mmHg]

18.7

3.5

13.0 - 26.2

Pressure Drop
[%]

58.1%

7.7%

39.2% - 69.7%

RT [sec]

6.36

3.75

3.4 - 16.1

Time to AVP
[sec]

7

1

6.0 - 9.0

For the valve geometry with ‘no sinus’ a mean pressure drop of 58.1% was achieved,
with 90% of valves tested having a drop of greater than 50%; however, the valves with a ‘sinus’
achieved a pressure drop that was 13.4% greater, and a 23.0% lower ambulatory venous pressure
as compared to the ‘no sinus’ valves. Overall, it can be concluded that the valves with a ‘sinus’
achieve more desirable AVP and pressure drop values. As with the ‘sinus’ geometry, all of the
‘no sinus’ valves satisfied the criteria to reach AVP in under 10 seconds (or steps). It is
hypothesized that the cause for these improved results is due to the ‘sinus’ geometry. The
geometry of the sinus seems to allow more blood simulant to flow around the leaflets, aiding in
closure the leaflets to the closed position. Valve with ‘sinus’ geometry had a 17.2% longer RT
than the mean RT for the ‘no sinus’ valves of 6.36 seconds. However, 30% of ‘no sinus’ valves
had a RT of 7.9 seconds or longer; as compared to 50% of the ‘sinus’ geometries.
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The pressure gradients measured across the two valve geometries tested are reported in
Table 3.3. This result appears to indicate the presence of a sinus in the valve correlates to an
improved valve closure.
Table 3.3 Measured pressure gradient for valve closure

∆𝑃 (mmHg)
6.16
5.23

Geometry
Sinus
No Sinus

From these tests, there is evidence that the ‘no sinus’ geometry is less effective at
meeting the criteria as a viable treatment option for CVI as compared to the ‘sinus’ geometry.
The only criterion in which the ‘no sinus’ valves produced better results was that of average time
to reach AVP, which was 0.7 seconds faster. However, only 10% of ‘no sinus’ valves had a
longer than 10 second RT time; compared to 25% for the geometry with a ‘sinus’. Additionally,
the ‘no sinus’ geometry was required to be tested are a resting pressure that was, on average, 1.4
mmHg lower and a steady state flow rate of 0.03 L/min less than the ‘sinus’ geometry. These
tuning adjustments infer a potential advantage for the presence of a sinus to assist in the effective
closing of the leaflets during ambulation.

Fatigue Test Results
To assess the potential viability of these printed valves as a treatment option for CVI, a
fatigue test was performed on both valve geometries. The testing was conducted under the same
system parameters and tuning as previously discussed. The valves were exposed to repeated
cycles until failure of the valve occurred. Failure modes observed included: (1) dislocation of
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one or more leaflets or (2) development of a tear in the surrounding hydrogel material. Either of
these failures resulted in a stop of testing, and the total number of cycles until failure was
recorded. Only valves which were able to satisfy the clinical criteria were included in these
results. Any valve which failed during a pre-testing function check of the leaflets, using a
syringe, was excluded from fatigue test results. The result for the fatigue test is shown in Table
3.4.
Table 3.4 Number of cycles for failure analysis results

Fatigue Test Results
Mean

Standard Deviation

Range

Sinus (# of cycles)

1338

1685

18 - 5,440

No Sinus (# of cycles)

266

577

2 - 2,163

As mentioned previously, the fatigue test results consisted of continuously operating the
system with a 3-D valve as the ‘Test Section’. This procedure is the repeated opening and
closing of the valves simulating walking a longer distance, and the test was conducted until valve
failure. Shown in Figure 3.10 is a pre-failure, representative plot of a ‘sinus’ geometry which
was exposed to 3,600 repeated cycles of operation. This valve went on to lasted for a total of
5,440 cycles before failure of both leaflets.
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Figure 3.10 Fatigue test pressure plot for 'sinus' geometry

Figure 3.10 illustrates a dependable, competent valve to satisfy all pressure related
criteria, and additionally able to maintain the AVP value for a prolonged amount of time. The
valve maintained a mean AVP of 10.1 mmHg; a 75.8% pressure drop from resting. The RT was
measured as 11.3 seconds. Both of these parameters satisfy the desired criteria. As a result, this
valve verified that repeated cycles does not diminish a competent valve’s ability to operate; with
the exception of when the valve failed after a total of 5,440 cycles. All fatigue testing was
conducted with this procedure to properly evaluate each valve’s effectiveness over an extended
time period. Comparatively, on average the ‘sinus’ geometry greatly outperformed the ‘no sinus’
valves in terms of longevity before failure; 1338 cycles to 266 cycles, respectively. Both valve
geometries had a large range of lifespan.
In order to obtain more conclusive results, a Weibull distribution analysis was performed.
A Weibull analysis is commonly used in reliability engineering in order to estimate a product’s
lifetime, assess product reliability, and analyze the life cycle data of a product [41]. As a result, it
was determined that a Weibull distribution analysis was an appropriate method to analyze the
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results of the fatigue test in order to analyze the fatigue data quantitatively and to draw
conclusions. The failure rate for a Weibull distribution for a two-parameter case is shown by
Equation 3.1.
𝛽

𝑡 𝛽−1

ℎ(𝑡) = � �
𝛼 𝛼

(3.1)

where h(t) is the failure rate function, 𝛽 is the Weibull shape parameter, and 𝛼 represents the
Weibull characteristic life. The case of 𝛽 < 1 indicates a decreasing failure rate for the product,

a value of 𝛽 = 1 is a constant failure rate, and 𝛽 > 1 for an increasing failure rate. The
characteristic life, or the number of cycles, such that 63.2% of products have failed is given by 𝛼
[41, 45].

The sample size for the fatigue data included 24 samples for the ‘sinus’ geometry
(N=24), and 12 samples for the ‘no sinus’ geometry (N=12). The initial step in computing this
probability analysis was to “rank” all of the fatigue data in ascending order based on the number
of cycles. The valves which lasted the least number of cycles received a “rank” of one, while the
valve which lasted the longest received a “rank” equal to the sample size. With the cycle data
organized in this manner, the next step was to compute the “median rank” for each valve sample.
The “median rank” calculates a value for each sample which is related to the estimated
unreliability, due to the ordering based on the “rank,” and assumes a cumulative binomial
distribution [42]. That is, the “median rank” determines a ranked probability of failure for each
sample [43]. A binomial distribution is applied due to the data set having two mutually exclusive
outcomes; either a result is considered to be a ‘success’ or a ‘failure’ [44]. Bernard’s
approximation was used to calculate the “median rank” for each data point, and it is shown by
Equation 3.2.
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𝑀𝑀 =

𝑗−0.3

(3.2)

𝑁+0.4

where N is the sample size for the data set, j is the “rank” assigned to that sample, and MR is the
“median rank” [41, 42].
The numerical value for the “median rank” increases as the “rank” increases. This
signifies a direct proportionality between the value for the “median rank” and “rank”; as the
“rank” increases so does the “median rank”. As the “rank” increases, so does the number of
cycles before failure; increasing the probability that a product will fail. The next step is to take
the double logarithmic reciprocal of (1 − 𝑀𝑀) and the logarithm of the number of cycles for

each sample to linearize the data set [43]. This method will then allow for a regression analysis

to be performed, obtaining a prediction model (i.e. linear fit) for the data in the form of 𝑦 =

𝑚𝑚 + 𝑏.

The slope of this line determines the value for the Weibull shape parameter (𝛽). The
Weibull characteristic life (𝛼) was calculated using Equation 3.3.

𝛼=𝑒

𝑏
𝛽

−� �

(3.3)

where b is the y-intercept determined from linear fit, or prediction model, for the data [41]. For
more details on these calculations see Appendix A.
The plots for the logarithmic curves used to obtain the values for the 𝛽 and 𝛼 for the ‘no

sinus’ and ‘sinus’ geometries are shown by Figures 3.11 and 3.12, respectively. The results for 𝛽
and 𝛼 for each valve geometry is summarized in Table 3.5.
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Figure 3.11 Logarithmic plot for ‘no sinus’ geometry with fatigue data and the prediction model
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Figure 3.12 Logarithmic plot for ‘sinus’ geometry with fatigue data and the prediction model

The R2 values, how closely the linear fit (prediction) models the experimental data, were
0.946 and 0.911 for the ‘no sinus’ and ‘sinus’ plots, respectively. These R2 values indicate a good
overall fit of the data, as a value of 1.0 signifies a perfect correlation between the linear fit and
the experimental data. Additionally, the Root Mean Square Error (RMSE) was calculated for the
linear fit. The RMSE values were determined to be 0.252 and 0.346 for the ‘no sinus’ and ‘sinus’
plots, respectively. A normalized RMSE (σ) was also calculated. This value represents the
relative error across the data set. This value was determined to be 6.1% for the ‘no sinus’ and
10.3% for the ‘sinus’ geometry. More details on the calculations of the RMSE and R2 parameters
are available in Appendix C.
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Table 3.5 Weibull coefficients for valve geometries

Sinus

𝛽

𝛼

0.590

937

No Sinus

0.589

156

The Weibull shape parameters (𝛽) for both geometries agree within 0.17% of one

another. As previously mentioned, a value less than 1 for 𝛽 indicates a decreasing probability of

failure. This aligns very well with the observed trends for both geometries; either valves at the
beginning of fatigue testing (i.e. less than 50 cycles) or lasted for hundreds, sometimes thousands
of cycles.
The valves performed significantly differently in terms of mean and maximum number of
cycles; as also shown earlier in Table 3.3. The mean value obtained for the ‘sinus’ geometry was
492% greater than that for the ‘no sinus’. Additionally, the maximum life cycle of the ‘sinus’
was a 152% increase over the ‘no sinus’ geometry. These results also agree with the Weibull
characteristics life (𝛼); in which 63.2% of ‘sinus’ valves are predicted to last for 937 cycles, as

compared to 156 cycles for the ‘no sinus’ geometry. If the valves which failed in less than 50
cycles are excluded from the data due to the assumption of a manufacturing defect, the values for
the Weibull shape parameter changes. The number of cycles at which 63.2% of valves are
predicted to fail after increases to 1,407 and 328 cycles for the ‘sinus’ and ‘no sinus’ geometries,
respectively.
To further illustrate the difference in the life cycles for the two geometries during the
fatigue testing; a plot of the “Probability of Survival” versus “Number of Cycles” was created
(shown by Figure 3.13).
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Figure 3.13 Probability of Survival versus Number of Cycles for both ‘sinus’ and ‘no sinus’ geometries from the Weibull
model of the data

This figure agrees with the observed trend in the fatigue testing. Initially, there is a steep
slope in the curve due to immediate failures; however, the slope decreases as predicted by the 𝛽

coefficient. Nevertheless, it can be statistically concluded that most valves have a high
survivability rate early on in the testing; with the obvious exception of valves which failed in less
than 50 cycles. Additionally, after a large number of cycles the probability of survival
approaches a value of zero because eventually all valves failed. Zooming in one the bottom left
area of the probability of survival plot (shown in Figure 3.14) illustrates the location of the two
Weibull coefficients (𝛼 𝑎𝑎𝑎 𝛽), showing the number of cycles in which 63.2% of valves are
predicted to fail for both designs.
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Figure 3.14 Zoomed in plot of Figure 38; illustrating the location of the two Weibull coefficients

Summary of Results
In summary, both valves appear to meet the desired pressure related criteria. However,
the ‘sinus’ valves outperformed the ‘no sinus’ ones in regards to average RT and AVP. The only
criteria in which the ‘no sinus’ valves were better performing was in the average time to reach
AVP; albeit only marginally better. The ‘sinus’ geometries had 50% of valves with RT of 7.9
seconds or longer, as opposed to 30% for the ‘no sinus’. Additionally, the AVP for the ‘sinus’
geometry was 23.0% lower with a 13.4% greater pressure drop in comparison to the ‘no sinus’
geometry.
The ‘sinus’ geometries were predicted to have a 63.2% chance of failure at 937 cycles; as
compared to 156 cycles for the ‘no sinus’ geometry. The life cycles of the valves are currently
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far too short to be a feasible option for treatment of CVI. These large variation in performance is
hypothesized to be a result of a structural defect in the printing, or due the different valve
geometries (sinus or no sinus) which cause higher stress levels and concentrations to develop in
the ‘no sinus’ valve; as compared to the ‘sinus’ valve. This hypothesis appears plausible because
the fatigue tests were consistently favored toward the ‘sinus’ geometry. Nonetheless, for proof of
concept both valve geometries performed well enough to meet the pressure related criteria; albeit
at a scaled down pressure.
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CHAPTER FOUR
CONCLUSION
The overall hypothesis for this thesis was satisfied as the 3-D printed valves produced
desirable pressure related responses; signifying a healthy patient. However, this required the
resting pressure to be reduced by 50% from the clinically measured value. All of the four
research objectives were satisfied in this study: (1) testing valves for AVP, RT, and time to AVP,
(2) test a significant sample size to determine consistency of valve performance, (3) perform a
fatigue test to determine the life cycle of the valves, and (4) compare any functional differences
between the two valve geometries.
The two valve geometries both satisfied the pressure related criteria of time to AVP,
AVP, and RT at the reduced system pressures. However, the ‘sinus’ geometry outperformed the
‘no sinus’ geometries by a significant margin in all criteria other than time to AVP. The ‘no
sinus’ geometry required a lower resting pressure and flow rate to properly achieve the desirable
pressure and time criteria, which provides for the basis that the existence of a sinus in the valve
design has an effect on the operating capabilities of the valves. Based on this data, the 3-D
printed valves appear to be the better option for treatment of CVI. A large sample size of 19
‘sinus’ and 10 ‘no sinus’ valves were tested for the pressure related criteria and a statistical
analysis was performed; determining the ‘sinus’ geometry produced better results. The Weibull
distribution analysis concluded that both valves had Weibull shape parameters (𝛽) which were
within 1% of one another; both indicating a decreasing failure rate of the valves. In other words,
if a valve did not fail in 50 cycles or less, its probability for surviving a large number of cycles
was good. It was also determined that 63.2% of ‘sinus’ and ‘no sinus’ valves were predicted to
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fail after 937 cycles and 156 cycles, respectively. This statistical conclusion was based off of the
values obtained Weibull characteristic life (𝛼) for both geometries. Neglecting valves which

failed in less than 50 cycles, for the purpose of assuming these valves had a major manufacturing
defect, the value for (𝛽) increases to 1,407 cycles for the ‘sinus’ geometry and 328 cycles for the
‘no sinus’ geometry.

In conclusion, the results of the fatigue test are concerning as a vein valve needs to
perform during years of operation; for millions of cycles. Moreover, the initially failure rate was
high for both valves; although higher in the ‘no sinus’ geometry. This conclusion is worth
mentioning because if the initial failures due to manufacturing “defects” can be eliminated and
improvements made to the valve strength and reliability, these valves may have potential for
transplantation. Nevertheless, the main objective of this research was to test the functionality of
the 3-D printed valves as the design improves incrementally.
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CHAPTER FIVE
RECOMMENDED FUTURE WORK
Several improvements could be made to this work. One improvement might be to change
the fatigue testing procedure. The suggested change it to conduct testing of the valves for a
smaller number of cycles (i.e. 100) then allowing the venous pressure to recover back to its
steady state value before testing another set of cycles. This procedure is hypothesized to be more
realistic in nature, to mimic a patient moving around intermittently with occasional sitting in
between exercising.
Although the Weibull analysis on the fatigue testing provided conclusive data on the
more effective valve in terms of life cycle, it is recommended that a detailed Finite Element
Analysis (FEA) be performed on the structure of the valves. This analysis will provide insight
into the existence of a structural weakness, a point of stress concentration, or the development of
residual stresses which cause valves to fatigue and fail at an unacceptably low number of cycles.
This will provide useful information into possible design and manufacturing improvements of
the valves.
To better understand why the ‘sinus’ geometry performed better, or why the ‘no sinus’
underperformed in comparison, in the clinical criteria flow visualization using particle image
velocimetry (PIV) to test for stagnation or turbulence in the flow may be necessary. Other
medical concerns with these 3-D printed valves could be with the development of thrombi (blood
clots) due to the porous nature of the gels. This testing could be conducted by using blood
instead of the saline solution as a blood simulant.

69

Lastly, additional work is recommended to improve the overall pressure handling of the
valves. The current valves are limited to one-half the full scale pressure as measured clinically in
an adult patient. In order to consider these valves for possible treatment and transplantation, the
necessary improvements to the pressure handling and life cycle must be addressed.
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APPENDIX A: WEIBULL ANALYSIS CALCULATIONS
The procedure for calculating a Weibull distribution for a life cycle analysis using
Microsoft Excel was done as follows:
1. Create a new Excel workbook. In call A1 enter the title: “No Sinus Cycles.” In this
column enter the fatigue data in any order. Next, sort the data in ascending order.
2. In cell B1 enter the title: “Rank.” With the cycle data in column sorted in ascending
order, assigned a value of 1 for the “rank” of the valve with the least number of cycles;
this should be cell B2. In cell B3 enter the formula: = 𝐵2 + 1 and drag that down. This

will assign an increasing value for the “rank” based on which valves lasted longer. The

valve with the largest number of cycles should receive the highest “rank” valve. For the
‘no sinus’ geometry the largest rank was 12.
3. In cell C1 enter the title: “Median Ranks.” In cell C2 enter the formula: = (𝐵2 −

0.3)/(12 + 0.4). Drag this formula down to compute the “median rank” for each sample
based on the Bernard’s approximation. B2 is the “rank” for each sample. The 12 in the
denominator is the number of samples.

4. In cell D1 enter the title: “1/(1-Median Rank).” In cell D2 enter the following formula to
compute this parameter: = 1/(1 − 𝐶2). Draw this formula down to compute this value
for each sample.

5. In cell E1 enter the title: “ln(ln(1/(1-Median Rank))).” This column will be used to
compute the double logarithm of the values in column D. The formula for this step is as
follows: = 𝐿𝐿(𝐿𝐿(𝐷2)). Drag this formula down.

6. In cell E1 enter the title: “ln(Cycles).” In cell F2 enter the formula: = 𝐿𝐿(𝐴2) to
calculate the natural logarithm of the values column A. The justification for the use of
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natural logarithms in Steps 5 and 6 is to linearize the data such that a linear regression
analysis can be performed.
7. The data should look like the following:

No Sinus
Cycles
2
6
10
45
57
65
80
121
196
210
242
2163

Rank
1
2
3
4
5
6
7
8
9
10
11
12

Median
1/(1-Median
Ranks
Rank)
ln(ln(1/(1-Median Rank))) ln(Cycles)
0.056451613
1.05982906
-2.845458285
0.693147181
0.137096774
1.158878505
-1.914247621
1.791759469
0.217741935
1.278350515
-1.404170849
2.302585093
0.298387097
1.425287356
-1.037403987
3.80666249
0.379032258
1.61038961
-0.741337623
4.043051268
0.459677419
1.850746269
-0.485175833
4.17438727
0.540322581
2.175438596
-0.252018579
4.382026635
0.620967742
2.638297872
-0.03032111
4.795790546
0.701612903
3.351351351
0.190094315
5.278114659
0.782258065
4.592592593
0.421630212
5.347107531
0.862903226
7.294117647
0.686660297
5.488937726
0.943548387
17.71428571
1.055834013
7.679251426

8. To perform the linear regression analysis, go to the Data tab in Excel. Select Data
Analysis and choose the Regression option.
1. For the “Input Y Range” select column E1:E13.
2. For the “Input X Range” select column F1:F13.
3. Select the following options: labels, new worksheet ply, and line fit plots.
*See the image below for more details on steps a, b, and c.
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4. Select OK to perform the regression analysis.
9. A new sheet in the workbook will be created that includes a plot of the experimental data
and the prediction (or linear fit) line. An image of what the new sheet should look like is
shown below.
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10. In cell B19 enter the formula: = 𝐵18. This value of the Weibull shape parameter (𝛽) and
was obtained from the slope of the linear regression analysis of the data.
𝐵17

11. In cell B20 enter the formula: = 𝐸𝐸𝐸(− 𝐵18). This value of the Weibull characteristic
life (∝).

12. In a new sheet of the workbook, enter the Alpha and Beta in cells A2 and A1,
respectively. Enter the values for the Weibull parameters in the cells A1 and A2.
13. In cell titles: “Cycles”, “Survival Probability”, and “Reliability” in cells D1, E1, and F1,
respectively.
14. In cell D2 enter the value of 0. In cell D3 enter the formula = 𝐷2 + 100. Drag this down
until the number of cycles is 2,220.

15. In cell E2 enter the formula = 𝑊𝑊𝑊𝑊𝑊𝑊𝑊(𝐷2, $𝐵$1, $𝐵$2, 𝑇𝑇𝑇𝑇).
16. In cell F2 enter the formula = 1 − 𝐸2.

17. Create a plot of the data in columns D and F of this sheet. This will create a plot
illustrating the probability of survival versus cycles. As the number of cycles increases,
the probability of survival decreases.
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APPENDIX B: OPERATING THE MOCK CIRCULATORY SYSTEM
The setup procedure is as follows:
1. Turn on the power for the flow meter. Turn off the alarm for the flow meter, this
is necessary for the flow meter to operate. Per the instructions, the flow meter
requires a 20-30 minute warm up period before measurements can be taken.
2. Turn on high pressure air supply. A Pressure regulator on the wall is used to
adjust the pressure of the air used in the muscle pump.
3. Turn on the water pump.
i. Note: during operation of the system it is important that the source head
tank remains at a constant fluid level. This is achieved by increases the
voltage to the water pump until the water level just barely reaches the
overflow mark. This is necessary to ensure a constant source pressure.
4. Open the NI LabView VI. An image detailing the components of the LabView
program is on the next page.
5. Insert the desired ‘Test Section’ to the system.
6. Purge the system of any air bubbles present in the fluid.
7. Adjust resistance and compliance values as necessary to obtain the desirable
system parameters (see Table 2.3 for resistance and compliance values).
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File name
Cycle length
% of cycle length in which
calf muscle vein is collapsed

Venous flow
rate

Delay: length of time until
muscle pump begins operation
Venous pressure
Start/Stop operation

76

APPENDIX C: STATISTICS AND UNCERTAINTY ANALYSIS
R2 Value
An R2 value represents how closely the linear regression line fits the measured data points
in an experiment. The R2 value is the square of the correlation coefficient of the linear regression
analysis. The correlation coefficient r is determined Equation C.1.

𝑟=

∑(𝑥𝑖 −𝑥̅ )(𝑦𝑖 −𝑦�)

(C.1)

�∑(𝑥𝑖 −𝑥̅ )2 ∑(𝑦𝑖 −𝑦�)2

A value of r of +/- 1.0 represents a perfect correlation between the data and the linear fit.
To calculate the measured R2 value, the correlation coefficient r is squared. An R2 value of 1.0
represents a perfect fit of the data.
Root Mean Square Error (RMSE)
The equation used to calculate the root mean square error (RMSE) is Equation C.2.

𝑅𝑅𝑅𝑅 = �∑

(𝑦𝑖 −𝑦𝑐𝑐 )2

(C.2)

𝑁

A normalized RMSE was calculated to determine using Equation C.3. This value
quantifies the relative error of the linear fit over the range of the data set.

𝜎=

𝑅𝑅𝑅𝑅

𝑦𝑚𝑚𝑚 −𝑦min

∗ 100%

(C.3)
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